Michael O'Riordan Michael O'Riordan joined theheart.org as a medical journalist in 2003, after completing his master's degree in journalism at the University of British Columbia, specializing in ...
September 18, 2007 (Amsterdam, the Netherlands) - Even in nondiabetics, increased HbA1 c levels are associated with a significantly increased risk of nonfatal cardiovascular disease after other ...
Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results